[1] Interferon is contraindicated in decompensated cirrhotics for safety reasons,
and telaprevir
and boceprevir have been shown in the TARGET
and CUPIC studies to be very difficult to use in a decompensated cirrhosis population.[10,11]
For genotype 1 and 4 HCV–infected individuals, current data support use of the combination of ledipasvir/sofosbuvir and ribavirin for 12 weeks with possible extension to 24 weeks in the case of previous sofosbuvir failure.